Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
40.78
-1.27 (-3.02%)
At close: Dec 12, 2025, 4:00 PM EST
41.68
+0.90 (2.21%)
After-hours: Dec 12, 2025, 4:39 PM EST
Rigel Pharmaceuticals Revenue
Rigel Pharmaceuticals had revenue of $69.46M in the quarter ending September 30, 2025, with 25.59% growth. This brings the company's revenue in the last twelve months to $282.08M, up 79.13% year-over-year. In the year 2024, Rigel Pharmaceuticals had annual revenue of $179.28M with 53.38% growth.
Revenue (ttm)
$282.08M
Revenue Growth
+79.13%
P/S Ratio
2.58
Revenue / Employee
$1,719,976
Employees
164
Market Cap
740.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 179.28M | 62.40M | 53.38% |
| Dec 31, 2023 | 116.88M | -3.36M | -2.79% |
| Dec 31, 2022 | 120.24M | -28.99M | -19.43% |
| Dec 31, 2021 | 149.24M | 40.62M | 37.39% |
| Dec 31, 2020 | 108.62M | 49.33M | 83.21% |
| Dec 31, 2019 | 59.29M | 14.78M | 33.20% |
| Dec 31, 2018 | 44.51M | 40.03M | 892.62% |
| Dec 31, 2017 | 4.48M | -15.90M | -78.00% |
| Dec 31, 2016 | 20.38M | -8.51M | -29.46% |
| Dec 31, 2015 | 28.90M | 20.65M | 250.24% |
| Dec 31, 2014 | 8.25M | 1.10M | 15.38% |
| Dec 31, 2013 | 7.15M | 4.90M | 217.78% |
| Dec 31, 2012 | 2.25M | -2.50M | -52.63% |
| Dec 31, 2011 | 4.75M | -120.25M | -96.20% |
| Dec 31, 2010 | 125.00M | 124.25M | 16,566.67% |
| Dec 31, 2009 | 750.00K | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | 12.60M | -20.87M | -62.36% |
| Dec 31, 2006 | 33.47M | 16.95M | 102.55% |
| Dec 31, 2005 | 16.53M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RIGL News
- 5 days ago - Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition - PRNewsWire
- 16 days ago - Rigel Pharma: Q3 Earnings Showcase Robust Growth - Seeking Alpha
- 16 days ago - Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference - PRNewsWire
- 25 days ago - Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology - PRNewsWire
- 4 weeks ago - Rigel to Present at the Jefferies Global Healthcare Conference in London - PRNewsWire
- 5 weeks ago - Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 5 weeks ago - Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition - PRNewsWire